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Background: Glycated hemoglobin is the indicator of long-term diabetes control and a 
value below 7 percent is recommended by the American Diabetes Association (ADA) to 
reduce cardiovascular complications.  Diabetic patients have a two- to four-fold risk of 
cardiovascular disease and approximately two-thirds of diabetic patients die as a result of 
cardiovascular complications.  Three large prospective randomized controlled long-term 
trials within the last decade reported no significant reduction in cardiovascular 
complications in type 2 diabetic patients by intensive glycemic control.  To the author’s 
knowledge, no known retrospective studies have examined the association between mean 
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serial glycated hemoglobin and coronary atherosclerosis (CA) or acute coronary 
syndromes (ACS).  
Objective: This study was designed to determine the association between mean serial 
glycated hemoglobin with incident CA or ACS in type 2 diabetic patients after 
controlling for age, gender, hypertension, low density lipoprotein cholesterol (LDL-C), 
microalbuminuria, aspirin use, statin use, insulin use, tobacco use, and body mass index 
(BMI). 
Methods: The study was a retrospective cohort database analysis using the Austin Travis 
County CommUnityCareTM clinics’ electronic medical record for the time period between 
October 1, 2004 and September 30, 2009.  The primary outcome of the study was the 
incidence of CA or ACS and the primary independent variable was glycated hemoglobin 
(<7% vs. ≥7%).  The study subjects included type 2 diabetic patients aged 30 to 80 years 
with at least one glycated hemoglobin value per year for a minimum of two consecutive 
years.  Study subjects were excluded if CA or ACS occurred within six months of the 
index date (i.e., first glycated hemoglobin).  Logistic regression analysis was used to 
address the study objective. 
Results: Overall, 3069 subjects met the study inclusion criteria with a mean follow-up 
period of approximately two years.  Two percent (N=62) of the subjects had incident CA 
or ACS.  After controlling for age, gender, hypertension diagnosis, LDL-C, 
microalbuminuria, aspirin use, statin use, insulin use, tobacco use and BMI, there was no 
significant association (OR=1.026, 95% CI=0.589-1.785, p=0.9289) between mean serial 
glycated hemoglobin and the incident diagnosis of CA or ACS.  Increasing age 
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(OR=1.051, 95% CI=1.025-1.077, p<0.0001), male gender (OR=1.855, 95% CI=1.105-
3.115, p=0.0195) and normal weight (normal or underweight compared to obese: 
OR=0.122, 95% CI=0.017-0.895, p=0.0438) were significantly associated with incident 
CA or ACS.  
Conclusions: Mean serial glycated hemoglobin (comparing ≥7% to <7%) was not 
significantly associated with CA or ACS over a mean follow-up period of approximately 
two years.  Until more evidence becomes available, clinicians and diabetic patients 
should target glycated hemoglobin level below or close to 7 percent as recommended by 
the ADA soon after diagnosis while concomitantly controlling nonglycemic risk factors 
of cardiovascular disease (statin use, aspirin use, blood pressure control, smoking 
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CHAPTER  ONE:    INTRODUCTION AND LITERATURE REVIEW 
 
1.1  CHAPTER OVERVIEW 
 This chapter provides a detailed review of the literature on the effect of blood 
glucose control in both diabetic and non-diabetic patients on the incidence of coronary 
heart disease.  The chapter begins with a table that lists the abbreviations used (Table 
1.1), followed by a brief background of type 2 diabetes.  This is followed by a review of 
the microvascular and macrovascular complications of type 2 diabetes.  Then the 
literature regarding the association of glycated hemoglobin with coronary heart disease in 
both diabetic and nondiabetic patients is presented.  The chapter ends with the statement 












Table 1.1  Abbreviations and Acronyms Used in Chapters One to Four 
AACE American Association of 
Clinical Endocrinologists  
HbA1C Glycated hemoglobin 
ACCORD Action to Control 
Cardiovascular Risk in 
Diabetes 
 
HDL High-density lipoprotein 
ACEI Angiotensin-converting 
enzyme inhibitor  
HDL-C High-density lipoprotein 
cholesterol 
ACS Acute coronary syndromes 
 
IHD Ischemic heart disease 
ADA American Diabetes 
Association  
IFG Impaired fasting glucose 
ADVANCE Action in Diabetes and 
Vascular Disease: Preterax 
and Diamicron MR 
Controlled Evaluation  
 
IMT Intima-media thickness 
AMI Acute myocardial infarction 
 
LDL Low-density lipoprotein 
ARB Angiotensin receptor 
blocker  
LDL-C Low-density lipoprotein 
cholesterol 
BMI Body mass index 
 
MI Myocardial infarction 
CA Coronary atherosclerosis  
NSTEMI Non-ST-segment 
elevation  myocardial 
infarction 
CCA Common carotid artery 
 
NHIS National Health 
Interview Survey 
CDC Center for Disease Control 
and Prevention  
PVD Peripheral vascular 
disease 
CHD Coronary heart disease 
 
STEMI ST-segment elevation 
myocardial infarction 
CIMT Carotid intima media 
thickness  
T2DM Type 2 diabetes mellitus 
CRP C-reactive protein 
 
TG Triglycerides  
CVD Cardiovascular disease 
 
UA Unstable angina 
DCCT Diabetes Control and 
Complications Trial  
UKPDS United Kingdom 
Prospective Diabetes 
Study 
ESRD End-stage renal disease 
 
US United States 
FFA Free fatty acid 
 






1.2  BACKGROUND OF TYPE 2 DIABETES 
 
1.2.1  Epidemiology and Classification 
Type 2 diabetes mellitus (T2DM), a disorder of carbohydrate metabolism, is a 
chronic disease associated with poor cardiovascular outcomes.  Approximately 90 
percent of diabetes patients have T2DM and the remaining 10 percent have type 1 
diabetes, also known as insulin dependent diabetes.[1]  Diabetes prevalence is increasing 
in the United States (US).  In 2007, it was estimated that 23.6 million Americans or 7.8 
percent of the US population had diabetes.  In 2008, the Centers for Disease Control and 
Prevention (CDC) released new statistics stating that over 24 million Americans had 
diabetes.[2]  Although prevalence of diabetes is approximately equal for males and 
females, it differs across racial/ethnic categories.  The highest rate of diabetes is among 
Native Americans (16.5%) and Alaskan Natives (16.5%), whereas the lowest rates are 
among Asian Americans (7.5%) and Whites (6.6%).  The rate of diabetes in Blacks is 
11.8 percent and the rate among Hispanics is 10.4 percent. 
The leading cause of morbidity and mortality among T2DM or type 1 diabetic 
patients is cardiovascular disease (CVD), which consists of coronary heart disease 
(CHD), stroke, peripheral vascular disease (PVD), hypertension and congestive heart 
failure.[3]  Coronary heart disease consists of acute coronary syndromes (ACS) which 
includes unstable angina (UA) pectoris, acute myocardial infarction (AMI), and small 
vessel coronary artery disease.[4-5]  In 2004, approximately 68 percent of deaths in 
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diabetic patients were due to CVD, with CHD as the leading cause.[6]  Haffner et al. 
showed that the risk of MI in diabetic patients is equivalent to non-diabetic patients with 
previous history of MI [7] and long-term morbidity and mortality after an MI is worse in 
diabetic patients compared with non-diabetics.[8]  Diabetes is therefore considered a 
coronary artery disease risk equivalent, with a 10-year cardiovascular event risk greater 
than 20 percent.[9]  Other  risk factors for CVD in diabetic patients include age, 
hypertension, family history of early CVD, dyslipidemia, smoking, microalbuminuria, 
and obesity.[10-11]  Microvascular complications in diabetic patients are also predictors 
of CVD.[12]  According to the National Health Interview Survey (NHIS), approximately 
six million Americans 35 years and older with diabetes were affected with CVD.  Of 
those, 65 percent reported having CHD.[13]  Therefore, aggressive management of 
diabetes is needed to reduce the risk of CHD.   
 Glycated hemoglobin (HbA1C), an estimate of a patient’s average blood glucose 
level over the previous ten to twelve weeks, is the biological marker of diabetes control.  
An HbA1C value below seven percent is recommended by the American Diabetes 
Association (ADA) to reduce microvascular and macrovascular complications of 
diabetes.[14]  However, the association between HbA1C and incidence of ACS has not 
been consistent in both clinical trials and prospective epidemiological studies of diabetic 
and non-diabetic patients.[15]  No known retrospective cohort database studies in the 
literature have examined the association between mean serial values of HbA1C prior to 
first diagnosis of coronary atherosclerosis (CA) or ACS and incidence of CA or ACS.  
The retrospective study design (compared to clinical trials or prospective cohorts) has an 
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advantage of assessing “real-world” (effectiveness) outcomes.  The overall purpose of 
this study is to determine whether incident CA or ACS is associated with mean HbA1C in 
T2DM patients. 
 
1.2.2  Complications of Type 2 Diabetes 
Long-term morbidities of poorly controlled T2DM are microvascular and 
macrovascular complications.[16]  Microvascular complications include nephropathy, 
neuropathy and retinopathy; and macrovascular complications involve the vasculature of 
the cardiovascular system.  Coronary heart disease, PVD, increased carotid intima-media 
thickness (IMT) and stroke are the main macrovascular complications of diabetes. 
Diabetic patients are living longer and therefore have a high probability of developing 
diabetes complications in their lifetimes.  However, these vascular complications can be 
delayed or prevented by glucose control, in addition to the following interventions on 
modifiable risk factors; blood pressure control, regular physical activity, healthy diet, 
lipid control, smoking cessation and medications.  These include angiotensin-converting 
enzyme inhibitor (ACEI) therapy, statin therapy, and aspirin therapy when indicated.[16]  
After a mean follow-up of 7.8 years, the Steno-2 trial demonstrated that a multifactoral 
intervention aimed at the modifiable risk factors in type 2 diabetic patients with 
concomitant microalbuminuria decreased the risk of both cardiovascular and 




1.2.2.1  Microvascular Complications 
As mentioned above, microvascular complications include nephropathy, 
neuropathy and retinopathy.  In the US, diabetic nephropathy is the leading cause of end-
stage renal disease (ESRD), which requires dialysis or transplantation,[18]  with diabetic 
ESRD prevalence increasing from 24.4 per million population in 1980 to 634.8 per 
million population in 2007.[15]  Diabetic nephropathy increases morbidity and when 
diabetic nephropathy progresses to ESRD, it significantly increases morbidity and 
mortality.  Over 20 to 40 percent of diabetic patients develop ESRD after 15 to 20 years 
of diabetes onset.[18]  Data from pooled studies have shown that diabetic nephropathy is 
an independent risk factor for developing CVD among diabetic patients [19] irrespective 
of age, sex, blood pressure and lipid levels.[20]  An early marker for diabetic 
nephropathy is microalbuminuria (microalbumin/creatinine ratio).  Microalbuminuria is 
defined as urinary excretion of albumin of 20-200 micrograms per minute or proteinuria 
greater than  500 mg in a 24-hour urine collection.[10]  In addition, a spot urine test for 
microalbuminuria that utilizes a random (nontimed) sample is available.  This test is 
frequently employed to screen for nephropathy in the ambulatory setting because of its 
convenience. A ratio of 30-300 mg/g from the spot test is diagnostic of microalbuminuria 
(normoalbuminuria is a ratio < 30 mg/g).[18]  Hypertension and uncontrolled diabetes are 
associated with a decline in renal function [18].  With many diabetic patients having 
concomitant hypertension, there is also an additive risk of nephropathy.  New onset 
diabetic nephropathy or the progression to ESRD can be delayed with tight control of 
blood glucose and blood pressure.  Blood pressure medications (angiotensin converting 
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enzyme [ACE] inhibitors and angiotensin receptor blockers [ARBs]) have been shown to 
be renoprotective independent of their blood pressure lowering effect. In diabetic patients 
with microalbuminuria, ACE inhibitors and ARBs have been shown to decrease the 
progression from microalbuminuria to macroalbuminuria by approximately 60-70 
percent.[12] 
Diabetic neuropathy is a complication that affects the nerves in the nervous 
system.  A wide range of prevalence rates (5-100%) of diabetic neuropathy have been 
reported, depending on the diagnostic criteria.[21]  Most of the hospitalizations from 
diabetes complications are due to neuropathy because it accounts for 50-70 percent of 
lower limb amputations.  Diabetic neuropathy damages peripheral, motor, sensory and 
autonomic nerves; hence, it is a polyneuropathic condition.[10]  The most common 
neuropathy in diabetes patients is the peripheral neuropathy that presents initially as pain 
and tingling in the toes and worsens at night.[22]  This then progresses to loss of 
sensation in the feet and frequent foot ulcers, which lead to amputations.  Regular 
screening for diabetic neuropathy is essential for early detection.  Inexpensive and 
noninvasive devices for assessing nerve sensation in diabetic patients are available and 
screening methods include vibration, thermal energy and light touch sensation.[10]  The 
gold standard for diagnosing diabetic neuropathy is clinical electrophysiology[22], but 
most primary care physicians use the light touch sensation or the vibration methods in 
clinical practice.  In addition, several pharmacologic options are available for the 
treatment of neuropathic pain.  These include antidepressants (e.g., amitriptyline and 
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duloxetine), anticonvulsants (e.g., phenytoin, carbamazepine, gabapentin, pregabalin), 
and analgesics (e.g., tramadol and opioids).[21] 
In the US, diabetic retinopathy is the leading cause of blindness among 
individuals between the ages of 20-74 years.  Retinopathy is sometimes present at the 
time of diabetes diagnosis [23] and it is estimated that over 60 percent of T2DM patients 
will develop some level of retinopathy after two decades of diabetes onset.[23]  With 
diabetic retinopathy, damage to blood vessels in the retina of the eye occurs as a result of 
persistent hyperglycemia.  The early stages of diabetic retinopathy that do not affect 
vision are treatable and with subsequent tight blood glucose control,  the progression to 
blindness can be delayed.[23]  The ADA recommends referral of a diabetic patient to an 
ophthalmologist for a dilated eye examination immediately after diagnosis and then 
annually.  Annual referral to an ophthalmologist is recommended to ensure that new 
onset retinopathy can be detected early for treatment, and that patients with diabetic 
retinopathy receive the appropriate care.   
 1.2.2.2  Macrovascular Complications 
The common macrovascular complications of diabetes are collectively termed 
CVD (i.e., CHD, PVD, increased CIMT and stroke).  They are the leading cause of 
morbidity and mortality among diabetic patients.  Other risk factors for CVD in addition 
to diabetes are dyslipidemia, hypertension and smoking.  These coronary risk factors 
damage the inner most layer of the arterial vessel (i.e., endothelium) resulting in 
endothelial dysfunction which plays an important role in initiating the atherosclerotic 
process.[24]  A functional vascular endothelium resists clot formation, helps form 
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collateral circulation and regulates blood flow via production of nitric oxide, a 
vasodilator which primarily mediates vascular reactivity.[25]   
Atherosclerosis is a gradual process that occurs throughout a person’s lifetime  
and targets the large- and medium-sized arterial walls throughout the body, eventually 
manifesting itself as an ischemic event such as MI or stroke.[26]  Persistent high blood 
glucose levels over time in diabetic patients result in glucose binding to arterial wall 
proteins, which forms advanced glycation end products.  These products accumulate over 
time and progressively lead to increased arterial wall stiffness and structural changes that 
compromise wall function, accelerate atherosclerosis and increase the risk of arterial 
thrombotic complications.[25, 27-30]  Other proposed mechanisms by which diabetes 
impair endothelial function are oxidation of low-density lipoprotein (LDL), 
hyperinsulinemia[31], oxidative stress[32] and increased concentrations of free fatty 
acids (FFA).[25]   
Low-density lipoprotein is not the only cholesterol implicated as a risk factor for 
atherosclerotic ischemic heart disease (IHD).  The Copenhagen Male Study demonstrated 
that diabetic dyslipidemia (high LDL-C, low HDL-C, and high TG) was a more powerful 
predictor of atherosclerotic IHD than isolated increased LDL-C levels.[33]  Also, 
hyperinsulinemia depicted by high fasting plasma insulin concentrations is usually 
associated with high TG and low HDL-C.  Results of prospective and observational 
studies depict hyperinsulinemia as an independent predictor of ischemic heart 
disease.[31]  Furthermore, the effect of increased oxidative stress (a relative increase in 
oxygen free radicals) on endothelial dysfunction in atherosclerosis has been demonstrated 
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in a study that compared vascular superoxide production in diabetic and nondiabetic 
patients.  Guzik and colleagues reported that in diabetic patients, there is increased 
production by blood vessel endothelium of superoxide (surrogate for oxidative stress), 
resulting in decreased nitric oxide which scavenges the superoxide, [32] leading to 
endothelial dysfunction.  Finally, Steinberg and colleagues concluded from a study 
evaluating the effect of plasma FFA levels on endothelium-dependent vasodilation that 
elevated circulating FFA levels cause endothelial dysfunction hypothetically via an effect 
on the nitric oxide system.[34] 
The consequences of a dysfunctional endothelium include decreased release of 
chemicals like nitric oxide that reduce the risk of arterial thrombosis and increased 
release of prothrombotic agents including endothelin-1 and vascular and intercellular 
adhesion molecules.[24]  In addition, inflammatory monocytes differentiate into activated 
macrophages that convert LDL-C embedded in the arterial wall into foam cells called 
plaques.  Thus, heterogenous plaques are rich in lipids, connective tissue elements or 
debris.[35]  Activated macrophages release inflammatory cytokines that fuel the plaque 
formation process.  The macrophages also play a role in activating enzymes that digest 
the extracellular matrix around the embedded plaque leading to plaque instability, making 
it vulnerable to rupturing and causing an ischemic event.  It is important to note that over 
99 percent of cases of plaque rupturing result in clinically silent events, [24] and in the 
case of a symptomatic event, there are multiple plaque ruptures which are different from 
the culprit plaque.  Inflammation is a very important determinant of vulnerable plaques 
and it correlates with increased density and activity of macrophages at the site of the 
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plaque as well as levels of C-reactive protein (CRP).  The degree of thrombus formation 
determines whether the rupture of plaque will result in a symptomatic ischemic event and 
plaque rupture results in acute partial or total vascular blockage.[12]  Two types of 
thrombi can be formed: a platelet rich one (white clot) which only partially occludes the 
artery; or a fibrin-rich clot (red clot) that usually forms total occlusion of the arterial 
lumen.  These fibrin rich clots are larger because they are formed as a result of the 
activation of the coagulation cascade.[24]   
Carotid intima media thickness (CIMT) and aorta measured ultrasound are 
methods for assessment of the generalized atherosclerosis including CA.[10, 36]  CIMT 
testing is a noninvasive process that directly measures atherosclerotic changes in the 
carotid artery and thickness in the intima layer of the carotid artery has been correlated 
with CA.   CIMT testing has been utilized in clinical trials that have evaluated the effect 
of pharmacotherapeutic agents on the diagnosis and progression of atherosclerosis.  On 
the other hand, intravascular ultrasound can be used to directly examine the coronary 
arteries for atherosclerosis, but CIMT measurements are easier to perform.[37]   
Peripheral vascular disease is generally characterized by the absence of femoral 
pulses as a result of the partial or complete occlusion of the arteries supplying the lower 
periphery with blood.  Occlusion of arteries in the periphery is secondary to 
arthrosclerosis.  Symptoms include intermittent claudication, numbness and weakness of 
lower extremities, and painful ulcers.  The risk of PVD is proportional to the magnitude 
and duration of hyperglycemia and diabetic patients have two-to four-fold higher rates of 
PVD than the normal population.[38]  Other risk factors for PVD are dyslipidemia, 
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smoking, obesity, hypertension, chronic renal failure and physical inactivity.   
 Stroke occurs when there is disruption of blood flow to a part of the brain due to 
atherosclerotic narrowing of small arteries within the brain or the large arteries leading to 
the brain.  Adverse impact of diabetes on cerebrovascular arterial circulation increases 
the risk of stroke by 150 to 400 percent in diabetic patients, with the risk more profound 
in patients under 55 years.[38] 
With almost all types of CHD, CA causes the narrowing of the arteries that supply 
the heart muscle with blood.  The atherosclerotic thickening of arterial wall in CHD 
occurs in the endothelium of the artery and atherosclerotic plaque(s) progressively cause 
the narrowing of the vessel lumen.[36]  Acute myocardial ischemic states, as a result of 
CA, result in CHD.[24]  The universal symptom of a suspected CHD event is chest pain 
stemming from myocardial ischemia.  In both unstable angina (UA) and (non-ST-
segment myocardial infarction (NSTEMI), there is an imbalance of oxygenated blood 
demand and supply to a heart muscle as a result of partial occlusion of blood flow from 
atherosclerosis.  The decrease in oxygenated blood supply manifests in chest pain, with 
NSTEMI symptoms being more severe (i.e., results in the release into blood of either 
cardiac-specific troponins or muscle and brain fraction of creatine kinase) than that of 
UA.[4]  In most cases of ST-segment myocardial infarction (STEMI), the rupture of an 
atherosclerotic plaque leads to an immune response that forms a thrombus around the 
plaque.  The plaque together with the thrombus totally occludes blood flow through the 
coronary artery to a heart muscle, leading to chest pain.[35]  In the US, approximately 
two-thirds of patients with MI have NSTEMI and the remaining one-third have STEMI; 
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both of which are differentiated by an electrocardiogram.             
 
1.3  GLYCATED HEMOGLOBIN  AND CARDIOVASCULAR OUTCOMES 
 
1.3.1  Glycated  Hemoglobin 
Glycated hemoglobin is the accepted surrogate marker of long-term blood glucose 
control in diabetes patients.  Both the ADA  and the American Association of Clinical 
Endocrinologists (AACE) recommend utilization of  HbA1C to assess long-term diabetes 
control, but with slightly different goals (7% vs. 6.5% respectively).[39-40]  HbA1C  is an 
estimate of average blood glucose over the preceding ten to twelve weeks and is 
expressed as the percent of glycated hemoglobin in blood.[41]  Standardized HbA1C 
assays are used, hence HbA1C results are interpreted consistently worldwide.[14]  
However, individuals with sickle cell, hemolytic anemia, chronic malaria, major blood 
loss or frequent blood transfusion may have spurious HbA1C results as a result of 
increase red blood cell turnover.[42]  Normal HbA1C in a nondiabetic patient is less than 
six percent.[39]  Per the 2010 ADA Standards of Diabetes Care, HbA1C greater than or 
equal to six and half percent measured on two separate occasions is diagnostic of 
diabetes.[14]  Use of HbA1C for diagnosis of diabetes was recommended by the 
International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of 
Diabetes in 2009 [42] and the ADA added the recommendation to its 2010 
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guidelines.[14]  The ADA recommends target HbA1C less than seven percent in diabetic 
patients to prevent microvascular and macrovascular complications of diabetes and this is 
based on findings from epidemiological studies.  This target HbA1C corresponds to an 
average blood glucose of 154 mg/dL in the previous ten to twelve weeks.[41] 
 
1.3.2  Glycated Hemoglobin or Blood Glucose and Cardiovascular Outcomes 
 
1.3.2.1  Non-Diabetic Patients 
A German study that analyzed the relationship between fasting plasma glucose, 
CIMT and some atherosclerosis risk factors in 300 nondiabetic patients no longer had a 
significant correlation between fasting blood glucose and IMT after adjusting for age and 
sex.[43]  However, glycated hemoglobin has been associated with the incidence of CHD 
in nondiabetic patients.  A recent large Australian cohort study, by Adam et al., of 
nondiabetic patients showed a positive association between HbA1C >5.3 percent 
compared with patients with HbA1C ≤5 percent and incidence of CHD in both men and 
women, with a stronger association in women ( HbA1C 5.4-5.6% [odds ratio 2.5, 95% CI 
1.4-4.6] and HbA1C ≥5.7% [odds ratio 1.9, 95% CI 1.1-3.4]).  This association persisted 
after adjusting for impaired fasting glucose (IFG), hypertension, hypercholesterolemia, 
body mass index (BMI), waist circumference, and tobacco smoking.[44]  Similarly, 
Hoogwerf et al., demonstrated, in a cross-sectional study, that glucose was independently 
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associated with incidence of CHD in nondiabetic patients.  The results of the study 
showed that across the range of recommended fasting blood glucose levels (100-125 
mg/dL) divided into five quintiles (<79, 80-86, 87-92, 93-99, 100-125 mg/dL), there was 
a significant increase in CHD prevalence (p <0.001) with increasing range of fasting 
blood glucose levels.[45]  
1.3.2.2  Diabetic Patients 
Most of the morbidity and mortality for diabetes are a result of complications of 
atherosclerosis which manifests clinically in three vascular beds namely coronary 
arteries, peripheral arteries and extracranial carotid arteries.[38]  Apart from the fact that 
diabetes patients with no history of CHD have the same risk for future MI as do 
nondiabetic patients with history of CHD, diabetes also negates the female decreased risk 
for death from CHD.[25]  Larsen and colleagues reported a strong association between 
IMT of the CCA, a validated surrogate marker of preclinical CA, and long-term HbA1C 
(mean=8.2%, range=6.6-11.3%) in asymptomatic females with type 1 diabetes mellitus 
(r2=0.77, p<0.0001), but not males.[37]  The mean HbA1C, which was the predictor 
variable, was calculated from the first HbA1C each year and was measured prospectively 
for 18 years.  The authors could not explain their finding that long-term hyperglycemia 
was a stronger risk factor for the development of atherosclerosis in women than in men.  
In addition, Roger and colleagues conducted an anatomical study of atherosclerosis using 
an autopsied population in the Olmstead county of MN to examine the association 
between diabetes and CA.[46]  Two measures (global coronary score and high grade 
stenoses) were employed to measure the prevalence of atherosclerosis.  There was a 
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higher prevalence of CA among diabetic individuals  than among nondiabetic individuals 
(prevalence ratio, PR=1.5, 95% CI 1.3-1.7, p<0.001).  Another important finding of this 
study was that approximately 75 percent of diabetic individuals without CAD had CA, 
which was similar to that observed in nondiabetic individuals with CAD.            
The authors of the Diabetes Control and Complications Trial (DCCT) reported 
that tight control of blood glucose assessed by the reduction in HbA1C reduces the risk of 
long-term microvascular complications in type 1 diabetic patients,[47] but did not 
demonstrate delay in macrovascular complications with tight glucose control.  Similarly, 
after a median follow up of ten years (interquartile range 7.7-12.4 years), the authors of 
the United Kingdom Prospective Diabetes Study (UKPDS) demonstrated that tight 
glucose control in T2DM patients using sulfonylurea or insulin to maintain a median 
HbA1C of seven percent versus conventional treatment of diet significantly reduced 
microvascular complications risk by 25 percent (p=0.0099), but not myocardial infarction 
(16% reduction in risk, p=0.052).[48]  However, after a mean follow-up of 17 years of 
the DCCT sample, the researchers reported that with tight glucose control, a 50 percent 
reduction in cardiovascular complications occurred.[49]  A major limitation of both the 
DCCT and UKPDS is the predominance of Caucasians, 96 and 80 percent respectively. 
In a review by Goff et al., the authors concluded that the relationship between 
lowering HbA1C and the incidence of CA or ACS (including CHD) in diabetic patients 
has not been consistent among studies.[50]  Prospective epidemiological studies 
demonstrated the incidence of CVD was strongly associated with the level of 
hyperglycemia as measured by glycated hemoglobin.[51]  A meta-analysis of 13 
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observational studies (N= 9,123) of diabetes patients (n=7,435 T2DM patients), after 
adjustment for risk factors, resulted in a significant increased risk of 18 percent (RR 1.18 
95% CI 1.10-1.26)  for CVD (CHD + stroke) for each percentage increase in HbA1C.[52]   
The Action to Control Cardiovascular Risk in Diabetes (ACCORD), Action in 
Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation 
(ADVANCE), and Veterans Affairs Diabetes Trial (VADT) are well designed studies 
within the last five years that reported no significant reduction in CVD (including CHD) 
with intensive control of blood sugar.[53] 
ACCORD was a prospective randomized study of 10,251 T2DM patients with 
either prior CVD (35%) or additional risk factors for CVD.[54]  Patients were on average 
62.2±6.8 years, and had a median HbA1C of 8.1 percent at baseline.  Patients were 
assigned to either intensive or standard therapy of glucose control.  The intensive therapy 
targeted HbA1C < 6 percent and standard therapy targeted HbA1C of 7 to 7.9 percent.  The 
primary outcome was a composite of nonfatal MI, nonfatal stroke, or death from CVD.  
Median HbA1C levels were 6.4 percent and 7.5 percent at one year in the intensive 
therapy and standard therapy groups, respectively, and were stable for the duration of 
follow-up.  Intensive therapy was discontinued after a mean of three and one-half years 
due to increased mortality.  There were 257 deaths reported in the intensive therapy 
group compared to 203 in the standard therapy group (HR 1.22; 95% CI 1.01-1.46; 
p=0.004).  Incidence of major CVD (i.e., the first occurrence of nonfatal MI or nonfatal 
stroke or death from cardiovascular causes) did not differ significantly between the 
intensive and standard therapy groups (p=0.16).  The increase in mortality in the 
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intensive therapy group was associated with the degree and pace of glucose lowering, 
which might have resulted in hypoglycemic episodes that led to patient deaths. 
ADVANCE was a prospective randomized controlled study of 11,140 T2DM 
patients who had either a history of major macrovascular or microvascular disease or one 
other risk factor for vascular disease.  Patients were randomized to either a standard 
glucose control (target HbA1C defined by local guidelines [n=5,569]) or intensive glucose 
control (target HbA1C ≤6.5% [n=5,571]) groups and were followed for a median duration 
of five years.[49]  Patients were on average 66.0±6.0 years and with average duration of 
diabetes (8.0±6.4 years). The mean ± SD (median) HbA1C was 7.5 ± 1.6 (7.2) percent at 
baseline.  At enrollment, 7.2 percent and 32.3 percent of patients had a history of 
macrovascular complications.  The primary endpoints were composites of major 
cardiovascular events (deaths from cardiovascular causes, nonfatal MI, or nonfatal 
stroke) and major microvascular events (nephropathy or retinopathy).  Mean HbA1C was 
6.5 percent in the intensive control group and 7.3 percent in the standard control group 
after a median follow-up of five years.  The HR in the intensive glucose control group 
compared to the standard glucose control group for combined major macrovascular and 
microvascular events was 0.90; 95% CI, 0.82 to 0.98; p=0.01.  However, for major 
macrovascular events alone, there were no significant differences between the two groups 
(HR with intensive glucose control 0.94; 95% CI 0.84 to 1.06; p=0.32).  The significant 
effect of intensive glucose control on combined major macrovascular and microvascular 
events, but not macrovascular events alone was attributed to the 21 percent relative risk 
reduction in nephropathy (microvascular event), hence intensive glucose control resulted 
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in a significant reduction in the incidence of major microvascular events in the 
ADVANCE trial.  Deaths from cardiovascular causes were similar between the two 
groups, a contrast with the ACCORD findings.  The similarity of macrovascular events 
and deaths between the two groups may be explained by the cumulative damage from 
high HbA1C values since diabetes diagnosis; therefore, the tight glucose control during 
the trial had little effect on macrovascular and mortality outcomes.  The ADVANCE trial 
has limited generalizeability to the US population because approximately 83 percent of 
the study participants were from Asia and Europe and with only four percent from North 
America.  
VADT was an open-label study that enrolled 1,791 military veterans with poorly 
controlled type 2 diabetes for a median follow up of 78 months.[53]  Patients were on 
average 60.4 ± 9 years, had diabetes for 11.5 ± 7.5 years, and average HbA1C of 9.4 ± 2.0 
percent.  Patients were randomly assigned to receive either intensive (n=892) or standard 
glucose control (n=899).  The primary outcome was time from randomization to first 
occurrence of a major cardiovascular event (i.e., MI, stroke, death from cardiovascular 
causes, congestive heart failure, surgery for vascular disease, inoperable coronary 
disease, and amputation for ischemic gangrene).  After follow up, the median HbA1C 
values in the intensive glucose control and standard glucose control groups were 6.9 
percent and 8.4 percent, respectively.  The hazard ratio in the intensive-therapy group for 
the time to first occurrence of first cardiovascular event was not significant (HR, 0.88; 
95% [CI], 0.74 to 1.05; p=0.14).  Duckworth and colleagues concluded from the VADT 
study that intensive blood glucose control in poorly controlled type 2 diabetes did not 
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significantly decrease the rates of major cardiovascular events.  A major limitation of the 
VADT study was that the study population was predominantly male (97%).   
Selvin et al conducted a case-cohort study using data from the ARIC 
(Atherosclerosis Risk In Communities) study.  The ARIC study was a four community 
US-based cohort study of 15,792 individuals who were between the ages of 45 to 64 
years at baseline.  Cardiovascular disease risk factor information was collected from the 
ARIC study subjects at baseline and study participants were followed for eight years.  In 
the prospective case-cohort study by Selvin et al, 1,321 adults without diabetes and 1,626 
adults with diabetes were evaluated in two independent groups (diabetic and nondiabetic) 
using the baseline HbA1C as the main predictor of CVD risk.  Four quintiles of HbA1C 
were created for the diabetic (<5.2%, 5.2 to <5.7%, 5.7 to <6.5%, 6.5 to <8.2% and 
≥8.2%) and nondiabetic (<4.5%, 4.5 to <4.8%, 4.8 to <4.9%, 4.9 to <5.2% and ≥5.2%) 
cohorts respectively.  After adjusting for covariates (i.e., age, sex, smoking, BMI, waist-
hip ratio, education, physical activity, systolic and diastolic blood pressure, hypertension 
medication, lipids), the relative risk (HR and 95% CI from Cox proportional hazards 
model) of CHD were significant for two quintiles and were 2.04 (1.30-3.19) for the 
HbA1C category 6.5 to <8.2%  and 2.37 (95% CI 1.50-3.72, p=0.01) for the highest 
quintile of HbA1C level compared with the lowest quintile.  In the nondiabetic cohort, the 
adjusted RR of CHD was not significant for each of the HbA1C quintiles.[55] 
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1.3.2.3  Mean Serial Glycated Hemoglobin and Cardiovascular Outcomes 
Little is known about the association between mean serial HbA1C values 
preceding an atherosclerotic coronary event and the occurrence of the coronary event.  
Studies that evaluated the effects of glycemic control in T2DM patients on CVD 
provided inconsistent evidence even though pooled analysis of prospective studies have 
shown continuous associations of HbA1C levels with the risk of major vascular 
events.[52]  Larsen and colleagues [37] observed a significant correlation between 18-
year average HbA1C and common carotid artery (CCA) IMT (an indicator of CA) [56]in 
type 1 diabetic females.  Also, several studies of T2DM patients have evaluated the effect 
of reduction in HbA1C (i.e., treating to a target HbA1C) on the incidence of cardiovascular 
events.  A meta-analysis of ten studies of T2DM patients showed an 18 percent increase 
in the risk of CVD for each one percent increase in HbA1C.  Also, a pooled analysis of 
six studies in the same meta-analysis found a significant increase in the risk of CHD by 
13 percent for each one percent increase in HbA1C.[52]  Furthermore, other prospective 
epidemiologic studies have shown that the benefit of blood glucose reduction in 
preventing CVD is demonstrated even in patients with baseline HbA1C values below six 
and half percent.[50][50]   
A mean serial HbA1C is being used as a predictor variable in this study instead of 
baseline HbA1C or median HbA1C in order to account for the contribution of individual 
HbA1C’s damage on the vascular system over the study period while taking into account 
when each HbA1C was measured.  In other words, the predictor variable will give equal 
weight to each patient’s HbA1C value recorded during the follow-up period.  The 
22 
 
DCCT/EDIC (Epidemiology of Diabetes Interventions and Complications) Study 
Research Group followed the DCCT cohorts in an observational study after the DCCT 
trail ended.  The researchers reported that, after a mean follow-up of 17 years of the 
DCCT data,   the decrease in HbA1C values in the intensive arm of the DCCT study 
significantly reduced the risk of CVD.[57]  This implies that the effect/benefit on 
diabetes vascular complications of a specific HbA1C achieved after an intervention may 
persist over a longer period of time.  Holman et al. confirmed the sustained benefit in 
reducing the risk of diabetic complications for up to ten years post the UKPDS 
study.[58]. The researchers found that even though the lower glycemic goal achieved in 
the intensive group of UKPDS eroded within one year (compared to conventional 
therapy) post trial follow-up, the significant reduction of diabetes complications achieved 
during the ten-year median follow-up of UKPDS persisted after ten years in 3277 
subjects of the original UKPDS cohort and even found a significant relative risk 
reduction of MI (15%, p=0.01) which was not found at the end of the original UKPDS 
study. 
Retrospective cohort database studies of T2DM patients have not tested whether 
the mean serial HbA1C values preceding the diagnosis of an atherosclerotic CHD can 
predict the risk of occurrence of the atherosclerotic CHD.  Retrospective analyses have 
the advantage of capturing “real-world” longitudinal data and will probably provide a 
more practical and generalizeable evidence regarding the relationship between incident 




1.3.3  Summary of Evidence 
Studies have shown increased risk of atherosclerosis in diabetes patients 
compared to the general population.  The landmark prospective clinical diabetes studies, 
DCCT and UKPDS, showed that aggressive management of blood glucose reduces the 
incidence of microvascular complications of diabetes [47-48], but per recent well-
designed large prospective studies (i.e., ACCORD, ADVANCE, VADT), the effect on 
cardiovascular disease (macrovascular complication) was not significant.[49, 53-54]  
However, it is known that the risk of a cardiovascular event in a diabetic patient is similar 
to that of a nondiabetic patient with a prior history of a cardiovascular event.[7]  In 
addition, for nondiabetic persons with normal HbA1C (i.e., < 7%)  and FBS, it has been 
shown that persons with HbA1C and  FBS in the upper limit of normal range have a 
higher risk of cardiovascular event than persons with values in the lower limit of normal 
range.[44-45]  Furthermore, an epidemiological study and reviews from pooled studies 
have shown substantial increase in the risk of cardiovascular events in T2DM patients 
with increasing HbA1C levels.[52, 55]  Finally, the mean or median follow-up of the 
randomized prospective studies of diabetes control and cardiovascular outcomes ranged 
from three and one-half to ten years [47-49, 53-54], long enough to detect significant 
reductions in macrovascular complications from aggressive management of diabetes in 




1.4  STATEMENT OF THE PROBLEM, OBJECTIVES AND HYPOTHESES 
 
1.4.1  Statement of the Problem 
Additional research is needed to provide more evidence on whether mean serial 
HbA1C values are useful predictors of incident CA or ACS (i.e., UA, NSTEMI, STEMI) 
in diabetic patients.  To the author’s knowledge, no retrospective database cohort analysis 
has used mean serial HbA1C as the predictor variable for incident CA or ACS.  
 
1.4.2  Aim of the Study 
The aim of this study is to determine the significance of mean serial HbA1C in 
predicting the diagnosis of incident CA or ACS in type 2 diabetic patients by comparing 
a cohort with mean serial HbA1C <7 percent to a cohort with mean serial HbA1C ≥7 
percent.  
1.4.3  Study Significance 
Results of this study may add to the body of literature regarding whether 
clinicians should target HbA1C levels close to the ADA goal of <7 percent at all times in 
all  or focus on specific diabetes patients soon after diagnosis.  Achieving this target in 
patients with difficult-to-control diabetes soon after diagnosis may reduce their risk of 
incident CA or ACS. 
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1.4.3.1  What Differentiates Study From Previous Studies 
This study had several unique features that distinguish it from other studies 
presented in this chapter.  First, the predominant population in the study was Hispanics 
with about an equal representation of African Americans (Blacks) and Whites.  Hispanics 
and Blacks are two minority ethnicities/races usually not adequately represented in non-
ethnic based clinical studies.  However, in the US, Hispanics and Blacks represent 
approximately 22 percent of diabetic patients compared to approximately 14 percent 
White and 14 percent Asians.[2]  Second, an outcome of this study is atherosclerosis 
which is a precursor to cardiovascular disease.  Atherosclerosis has not been studied as an 
outcome in most well-designed prospective studies probably because of its variability in 
time to becoming symptomatic.  This study’s inclusion of atherosclerosis as an outcome 
may further support the ADA guidelines. These guidelines recommend aggressive 
management of diabetes to prevent atherosclerosis and subsequent CHD because the 
prevalence of aggressive atherosclerosis among diabetic patients without established 
clinical CHD is similar to the prevalence among nondiabetic subjects with clinical CHD.  
Lastly, a retrospective cohort analysis using data obtained from routine patient follow-up 
is a more “real-world” approach (i.e., compared to treat-to-target in prospective studies) 
to follow the progression of diabetic patients (in terms of comprehensive management of 




1.4.4  Study Objectives and Associated Hypotheses  
The objectives and hypothesis of this study were: 
Objective One: To describe the demographic and clinical characteristics of T2DM 
patients with CA or ACS (i.e., UA, NSTEMI, and STEMI). 
 
Objective Two: To examine the relationship between incident diagnosis of CA or ACS 
and HbA1C.  
H02A1:  There is no statistically significant difference in incident diagnoses of CA or ACS 
between the HbA1C <7 percent and  HbA1C ≥7 percent groups.  
 
Objective Three: To determine the associations of incident CA or ACS with HbA1C in 
T2DM patients after controlling for age, gender, hypertension, LDL-C, 
microalbuminuria, aspirin use, statin use, insulin use, tobacco use, and BMI. 
H03A1: There is no statistically significant difference in incident diagnosis of CA or ACS 
between the HbA1C <7 percent and HbA1C ≥7 percent groups while controlling 
for covariates. 
H03B1: There is no statistically significant relationship between incident diagnosis of CA 
or ACS and age, while controlling for other covariates.  
H03B2: There is no statistically significant relationship between incident diagnosis of CA 
or ACS and gender, while controlling for other covariates. 
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H03B3: There is no statistically significant relationship between incident diagnosis of CA 
or ACS and hypertension diagnosis, while controlling for other covariates.  
H03B4: There is no statistically significant relationship between incident diagnosis of CA 
or ACS and LDL-C, while controlling for other covariates. 
H03B5: There is no statistically significant relationship between incident diagnosis of CA 
or ACS and microalbuminuria, while controlling for other covariates. 
H03B6: There is no statistically significant relationship between incident diagnosis of CA 
or ACS and aspirin use, while controlling for other covariates. 
H03B7: There is no statistically significant relationship between incident diagnosis of CA 
or ACS statin use, while controlling for other covariates. 
H03B8: There is no statistically significant relationship between diagnosis of CA or ACS 
and insulin use, while controlling for other covariates. 
H03B9: There is no statistically significant relationship between incident diagnosis of CA 
or ACS and tobacco use, while controlling for other covariates. 
H03B10: There is no statistically significant relationship between incident diagnosis of CA 





CHAPTER TWO:    METHODS 
 
2.1  CHAPTER  OVERVIEW 
The methodology used is described in the following order: study design, data 
source; study population and inclusion criteria; study cohorts, index date, and timeframe; 
study outcomes; study variables; and statistical analysis. 
 
2.2  INSTITUTIONAL  REVIEW  BOARD  APPROVAL 
The study was approved by the Institutional Review Board (IRB) of The 
University of Texas at Austin (IRB protocol number: 2009-07-0013) and permission was 
obtained from CommUnityCareTM in Travis County, Texas to utilize patient data.  A 
waiver of informed consent was obtained since the study will not impact the medical care 




2.3  STUDY DESIGN 
This study is a retrospective database cohort analysis of type 2 diabetic patients to 
examine the association between incident CA or ACS and HbA1C. Patients were 
stratified into two groups based on their HbA1c levels (HbA1C <7%, and HbA1c ≥7%).  
The patients in the group with mean serial HbA1C <7 percent served as the comparator 
group for analysis (see Figure 2.1).  
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2.3.1  Cohort Structure 













2.3.2  Data Source 
The data used in this study was obtained from the Travis County 
CommUnityCareTM clinics’ electronic medical record (EMR).  This database captures 
real-life, longitudinal data (provider notes, laboratory data and medications) on patients 
receiving primary care.  Thirteen of the sixteen CommUnityCareTM clinics formerly 
called City of Austin clinics are located in Austin, Texas.  They were established in 1970 
by the Austin City Council in partnership with the Travis County Commissioner's Court 
Study population 
Selected sample 
Diabetic patients with 
mean serial HbA1C <7% 
Diabetic patients with 







and officially earned a Federally Qualified Health Center (FQHC) status in 2001.  The 
clinics provide primary care, dental care, and family planning services to over 50,000 
indigent individuals in Travis County, with approximately 74 percent of patients being 
Hispanic, 12 percent Caucasian, 11 percent African American, and three percent other 
ethnicities.[59]  The EMR was initiated in 2004, and by 2007, it was fully implemented 
in all clinics.   
 
2.3.3  Study  Population 
Data was extracted from the CommUnityCareTM database for the time period 
between October 1, 2004 and September 30, 2009.  The year 2004 was used because it 
was when EMR implementation was initiated in CommUnityCareTM, and to 
accommodate for early and late adopters of EMR within the CommUnityCareTM system, 
data was supplemented from other databases.  The five-year time period of data 
extraction was used to maximize patient eligibility for the study.   
The inclusion criteria that were used for selecting patients are as follows: 
1. Type 2 diabetes patients aged between 30 and 80 years; 
2. At least two years of continuous enrollment in the CommUnityCareTM system; 
3. At least one HbA1C value each year for a minimum of two consecutive years 
during the study period; and 
4. No diagnosis of ACS or CA 6 months prior to the index date. 
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2.3.4  Study Cohorts, Index Date and Timeframe 
Two cohorts were created from the study sample based on mean serial HbA1C 
values over the study period.  The first cohort (comparator group) consisted of diabetic 
patients with mean serial HbA1C values less than 7 percent and the second cohort had 
patients with mean serial HbA1C values greater than or equal to 7 percent.  The cohort 
structure is shown in Figure 2.1.   The six-month period from October 1, 2004 to March 
31, 2005 served as the ‘wash-out’ period. Any eligible patient who had the outcome (CA 
or ACS) during the six-month pre-index period was excluded.  The earliest possible index 
date was April 1, 2005.  The index date for the patients with the outcome (i.e., incident 
diagnosis of CA or ACS) was the date of the first of consecutive HbA1Cs prior to the date 
of outcome and the end date was the outcome date.  The last consecutive HbA1C value 
must occur within 365 days prior to the outcome or on the day of the outcome.  For 
patients without the outcome, the index date for eligible patients is the earliest of 
consecutive HbA1Cs and the end date is the last of consecutive HbA1Cs.  
Eligible patients were followed for a minimum of two consecutive calendar years, 
but the criteria for the follow-up schedule and the index date differed for patients with the 
outcome and patients without the outcome.  Figure 2.2 illustrates the different scenarios 




Figure 2.2  Study Follow-up Schedule 
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2.4  STUDY ENDPOINTS 
 
2.4.1  Primary Outcome 
The primary outcome of the study was the risk (incidence) of CA or ACS in 
T2DM patients when the mean serial HbA1C <7 percent group was compared to the mean 
serial HbA1C ≥7 percent group, after adjusting for covariates (age, gender, hypertension, 
LDL-C, microalbuminuria, aspirin use, statin use, insulin use, tobacco use, and BMI).  
The comparator cohort mean serial HbA1C <7 percent was used in the study so that the 
study group with mean serial HbA1C ≥7 percent could be compared to the current 
standard of practice as recommended by the ADA.  An odds ratio was calculated from 
logistic regression to evaluate the primary outcome. 
 
2.4.1  Study Variables 
The dependent variables were CA or ACS, which consisted of UA, NSTEMI and 
STEMI.  The main independent variable of this study is HbA1C (dichotomized into <7% 
and ≥7% groups).  The covariates were age, gender, hypertension, LDL-C, 
microalbuminuria, aspirin use, statin use, insulin use, tobacco use, and BMI.  The study 
variables and operational definitions are listed in Table 2.1. 
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Table 2.1  Study Variables and Operational Definitions 





ACS (UA, NSTEMI, 
STEMI) or CA 
A diagnosis of any of the below: 
UA ICD-9: 411.1 & 413.9 
NSTEMI ICD-9: 410.7 
STEMI ICD-9: 410.0-410.6 & 410.8 











Age Age at index Years (continuous) 
Gender Male or female 
0= Male 
1= Female 
Hypertension ICD-9: 401.1 or 401.9 
0= No 
1= Yes 
LDL-C LDL-C closest to end date 
0= <100 mg/dL 
1= ≥100 mg/dL 
Microalbuminuria Microalbuminuria closest to end date 
0= <30 mg/g 
1= 30-300 mg/g 
Aspirin use 


















BMI BMI closest to the end date 1= <24.9 Kg/m
2 
2= 25.0-29.9 Kg/m2 
3= 30.0  Kg/m2 
Abbreviations:  ACS=acute coronary syndromes; BMI=body mass index; CA=coronary atherosclerosis; 
HbA1C= glycated hemoglobin; LDL-C=low density lipoprotein cholesterol;  NSTEMI=non-ST-segment 





2.5  STATISTICAL ANALYSES 
Continuous variables were reported as mean values ± SD.  Frequencies and 
percentages were utilized to present categorical variables (Objective 1).  In addition, a 
chi-square test was used to estimate the association between incident CA or ACS and 
each categorical covariate.  Similarly, a t-test was used to estimate the association 
between incident CA or ACS and age.  Pearson’s chi- square test was used to estimate the 
association between incident CA or ACS and HbA1C (Objective 2).  Logistic regression 
was used to estimate the association (i.e., odds ratios with 95% CI) between incident CA 
or ACS and HbA1C while controlling for covariates (Objective 3).  P-values <0.05 were 
considered statistically significant.  The assumptions of the Pearson’s Chi-Square tests 
are random sampling of the data, adequate cell sizes and independent observations.  No 
assumption was made about the distribution of the independent variables in logistic 
regression.  All statistical analyses were performed using SAS version 9.1.3.  The 





Table 2.2  Summary of Independent and Dependent Variables and Statistical Analyses 






Objective 1: To describe the demographic and clinical characteristics of type 2 diabetic 
patients with CA or ACS (i.e., UA, NSTEMI, and STEMI) 
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Objective 2: To examine the relationship between incident diagnosis of CA or ACS and 
mean serial HbA1C  





diagnoses of CA 
or ACS between 
the HbA1C <7 


















Abbreviations:  ACS=Acute coronary syndromes; BMI=body mass index; CA=coronary atherosclerosis; 
DV=dependent variable; HbA1C=glycated hemoglobin; IV=independent variable; LDL-C=low density 
lipoprotein cholesterol; NSTEMI=non-ST-segment elevation myocardial infarction; STEMI=ST- segment 












Table 2.2  Summary of Independent and Dependent Variables and Statistical Analyses, 
cont. 
 





Objective 3: To determine the associations of CA or ACS with mean serial HbA1C  in 
T2DM patients after controlling for age gender, hypertension, LDL-C, microalbuminuria, 
aspirin use, statin use, insulin use, tobacco use and BMI 
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between the HbA1C 
<7 percent and 
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Abbreviations:  ACS=Acute coronary syndromes; BMI=body mass index; CA=coronary atherosclerosis; 
DV=dependent variable; HbA1C=glycated hemoglobin; IV=independent variable; LDL-C=low density 
lipoprotein cholesterol; NSTEMI=non-ST-segment myocardial infarction; STEMI=ST- segment 





2.5.1  Sample Size Calculation 
To address Objective 2, a chi-squared analysis was performed and Objective 3 
employed logistic regression. Since logistic regression required the larger sample, the 
formula below was utilized to determine the sample size [60]:  
                      
            
Where: 
N=Number of subjects in the exposed group 
P=Incidence of the disease in the control population/year 
R=Minimum relative risk to be detected 
α=Type I error 
β=Type II error 
K=ratio of the number of subjects in the unexposed group to the number of 
subjects in the exposed group 
The α was set at 0.05 and β at 0.2 (resulting in 80% power).  Based on Avogadro 
et al., the incidence rate of first CHD event per 1,000 person-years among T2DM patients 
was 28.8 (95% CI 5.4–32.2) in men and 23.3 (20.2–26.4) in women.[61]  Thus, we 
examined calculated sample size based on minimum relative risk of 1.25, incidence of the 
disease in the unexposed at two percent, and used a ratio (2:1) of subjects in unexposed 
and exposed groups.  Based on these values, a minimum sample size of 2436 subjects 
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with 812 subjects being in the exposed cohort was needed to address the study objectives.  
The study setting, CommUnityCareTM clinics have a diabetes population aged 30 to 80 
years of approximately 9,800. 
 
Table 2.3  Sample Size Calculation 
Incidence 2% 
Relative risks 1.25 
Ratio of unexposed:exposed 2:1 
Sample size (unexposed:exposed) 1624:812 












CHAPTER THREE:    RESULTS 
 
3.1  CHAPTER OVERVIEW 
Chapter Three describes the demographic and clinical characteristics of the study 
population and results of the study objectives.  The selection of subjects meeting the 
inclusion and exclusion criteria will be provided.  Then, descriptive analyses of the 
demographic and clinical variables for the eligible patients will be presented.  Finally, the 
unadjusted results of the chi-square analyses and the adjusted results of the logistic 
regression analyses that examined the relationship between HbA1C and incident diagnosis 
of CA and ACS will be presented.   
 
3.1.1  Included Patients and Demographic Characteristics 
Data for this study was obtained from the Travis County CommUnityCareTM 
clinic database for the time period October 1, 2004 to September 30, 2009.  The six-
month period from October 1, 2004 to March 31, 2005 served as the ‘wash-out’ period.  
The profiles of 9838 T2DM patients were retrieved.  After applying the inclusion criteria, 
a total of 3069 patients were included in the final sample (see Table 3.1). The main 
reason for excluding eligible patients was lack of continuous enrollment (N=3297) 
followed by the inclusion criterion of at least one HbA1C value each calendar year for a 




Table 3.1 Selection of Patients Meeting Inclusion/Exclusion Criteria 




Number of T2DM patients   9838 
Lack of continuous enrollment for at least two 
consecutive years between April 1, 2005 and September 
30, 2009 
[3297] 6541 
Lack of at least one HbA1C value each year for two 
consecutive years 
[2673] 3868 
Number of patients with a diagnosis of ACS or CA 6 
months prior to index date 
[55] 3813 
Number of patients with diagnosis of ACS or CA more than 
1 year after of the last consecutive HbA1C date 
[107] 3706 
Number of T2DM patients <30 or >80 years old [186] 3520 
Number with casewise missing values [451] 3069 
 
 
3.2  OBJECTIVES 
 
3.2.1  Objective 1 Analysis (Descriptive Statistics) 
Objective 1 describes the outcome, demographic and clinical characteristics of 
T2DM patients included in the study sample.  Regarding the outcome variable, the 
majority (98%) of patients (N=3007) did not have a diagnosis of CA or ACS, while only 
two percent (N=62) had a diagnosis of CA or ACS.  The descriptive statistics for primary 
independent variable (i.e., HbA1C) and covariates for the entire sample (N=3069) and the 
two cohorts (i.e. with and without incident CA or ACS) are shown in Table 3.2.  The 
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entire sample statistics will be described, followed by a highlight of significant 
differences between the two cohorts.  
The mean ± SD HbA1C of all patients was slightly over the ADA recommended 
value (<7.0%) at 7.8%±1.7%.  The mean ± SD age of patients was 53.6±11.2 years, and 
females represented almost two-thirds (64.2%) of the entire cohort.  Hypertension 
(defined by ICD-9 codes 401.1 or 401.9) was present in the majority (81.2%) of patients 
and slightly over one-third (35.0%) had LDL-C levels ≥100 mg/dL.  A history of 
microalbuminuria > 300 mg/g was observed in 29.2 percent of patients.  Almost 45 
percent (44.6%) of patients had a history of aspirin use during the study period, while 
two-thirds (66.6%) were prescribed a statin.  The proportion of patients who received 
insulin was 33.5 percent and 12.5 percent used tobacco during the study period. Less than 
ten percent (9.5%) of patients were underweight to normal weight (BMI ≤ 24.9 kg/m2), 
26.8 percent were overweight (BMI range 25.0-29.9 kg/m2), and the majority of patients 
(63.7%) were obese (BMI ≥30.0 kg/m2). Among bivariate comparisons of independent 
variables and the outcome, there were three variables that were significant.  A t-test 
showed that patients with CA or ACS were significantly (p<0.0001) older than those 
without CA or ACS (59.0±8.9 years vs. 53.4±11.2 years, respectively).  A chi-square 
analysis revealed a significantly (p=0.0367) lower percentage of males with CA or ACS 
compared to males without CA or ACS.  Of those patients with CA or ACS, 48.4 percent 
were males while only 35.6 percent of patients without CA or ACS were males.  
Additionally, a chi-square analysis revealed a significantly (p=0.0001) higher percentage 
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of patients with hypertension among those with CA or ACS (100%) compared to those 


















Statistic Df p-value 
HbA1C  
(Mean ± SD) 7.8 ± 1.7 7.6 ± 1.5 7.8 ± 1.7  0.94a 3067 0.3463 
Age in years  
(Mean ± SD) 53.6 ± 11.2 59.0 ± 8.9 53.4 ± 11.2  4.82 a 65 <0.0001 
Male (%) 35.8 48.4 35.6   4.35b 1 0.0367 
Hypertension (%) 81.2 100.0 80.8 14.62b 1 0.0001 
LDL-C≥100 mg/dL (%) 35.0 27.4 35.1  1.58b 1 0.2083 
Microalbuminuriac (%) 29.2 30.7 29.1  0.07b 1 0.7953 
Aspirin use (%) 44.6 41.9 44.7  0.19b 1 0.6652 
Statin use (%) 66.6 71.0 66.5  0.53b 1 0.4647 
Insulin use (%) 33.5 32.3 33.5  0.04b 1 0.8347 
Tobacco use (%) 12.5 12.9 12.5  0.01b 1 0.9188 
BMI  
     ≤24.9 (%) 9.5 1.6 9.7  4.66b 2 0.0974 
     25.0-29.9 (%) 26.8       30.7       26.7 - - - 
    ≥30.0 (%) 63.7       67.7       63.6 - - - 
Abbreviations: ACS=acute coronary syndromes; BMI=body mass index; CA=coronary 
atherosclerosis; HbA1C=glycated hemoglobin; LDL-C=low density lipoprotein cholesterol 
a T-test 
b Chi-Square Test 
cMicroalbuminuria defined as urine albumin/creatinine ratio ≥ 30 mg/g 
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3.2.2.  Objective 2 Analysis (Chi-Square) 
Objective 2 was to examine the unadjusted relationship between incident CA or 
ACS and HbA1C.  A chi-square test (see Table 3.3) revealed no significant relationship 
between incident CA or ACS and HbA1C (χ
2 =0.30; df=1; p=0.5834).  Patients with 
incident CA or ACS had a slightly smaller proportion with HbA1C ≥7% compared to 
those without CA or ACS (58.1% vs. 61.5%, respectively).  The null hypothesis [H02A1: 
There is no statistically significant difference in incident diagnoses of CA or ACS 
between the HbA1C <7 percent and  HbA1C ≥7 percent groups] was not rejected.
 
 
Table 3.3 Chi-Square Analysis of Incident CA or ACS and HbA1C 
 CA or ACS 
HbA1C 
Yes 
      N          (%) 
No 
      N          (%) 
<7% 26 41.9 1158 38.5 
≥7% 36 58.1 1849 61.5 
Total 62 100.0 3007 100.0 
Abbreviations: ACS=acute coronary syndromes; 
CA=coronary atherosclerosis; HbA1C=glycated 
hemoglobin 




3.2.3.  Objective 3 Analysis (Logistic Regression) 
Logistic regression was used to determine the association between incident CA or 
ACS and HbA1C (i.e., <7% compared to ≥7%) in T2DM patients after controlling for age 
gender, hypertension, LDL-C, microalbuminuria, aspirin use, statin use, insulin use, 
tobacco use and BMI (See Table 3.4).  The overall logistic regression model was 
significant (χ2=30.51, df=11, p=0.0013); however, there was no significant difference 
between incident CA or ACS and HbA1C [Odds Ratio (OR)=1.026, 95% CI=0.589-
1.785, p=0.9289].  The null hypothesis [H03A1: There is no statistically significant 
difference in incident diagnoses of CA or ACS between the HbA1C groups (i.e., <7% 
compared to ≥7%), while, controlling for covariates] was not rejected.   
Covariate analyses results are detailed below with associated hypothesis test 
results shown in Table 3.4.  Note: Hypertension was deleted from the logistic regression 
model because all subjects with incident CA or ACS had hypertension (see Table 3.2), 
thereby making the logistic regression model unstable.  Age was significantly related to 
incident diagnosis of CA or ACS (OR=1.051, 95% CI=1.025-1.077, p<0.0001).  For each 
one year increase in age, subjects were 5.1 percent more likely to have incident CA or 
ACS.  Gender was significantly related to incident diagnosis of CA or ACS (OR=1.855, 
95% CI=1.105-3.115, p=0.0195).  Compared to females, males were 85.5 percent more 
likely to have incident diagnosis of CA or ACS.  Low density lipoprotein cholesterol was 
not significantly associated with incident CA or ACS (OR=1.262, 95% CI=0.712-2.237, 
p=0.4253), nor was microalbuminuria (OR=1.029, 95% CI=0.583-1.816, p=0.9220).  
Aspirin use during the study period was not significantly related to incident CA or ACS 
(OR=1.286, 95% CI=0.764-2.162, p=0.3438).  Similarly, statin use during the study 
period was not significantly related to incident CA or ACS (OR=0.932, 95% CI=0.529-
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1.642, p=0.8081).  Neither insulin use (OR=0.983, 95% CI=0.547-1.767, p=0.9554) nor 
tobacco use (OR=0.808, 95% CI=0.375-1.742, p=0.5858) during the study period were 
not significantly related to incident CA or ACS.  Compared to obese patients (BMI ≥ 
30.0 kg/m2) those who were under to normal weight (BMI <25.0 kg/m2), were 87.8 
percent less likely to be diagnosed with incident CA or ACS (OR=0.122, 95% CI=0.017-
0.895, p=0.0438).  However, there was no significant difference in incident CA or ACS 





Table 3.4  Logistic Regression Analyzing the Association of Mean HbA1C With 














HbA1C <7% 1.026 0.589-1.785 0.008 0.9289 Not Rejected 
Age 1.051 1.025-1.077 15.531 <0.0001 Rejected 
Male 1.855 1.105-3.115 5.460 0.0195 Rejected 
LDL-C<100mg/dL 1.262 0.712-2.237 0.636 0.4253 Not Rejected 
Normoalbuminura 1.029 0.583-1.816 0.010 0.9220 Not Rejected 
Aspirin nonuse 1.286 0.764-2.162 0.896 0.3438 Not Rejected 
Statin nonuse 0.932 0.529-1.642 0.059 0.8081 Not Rejected 
Insulin nonuse 0.983 0.547-1.767 0.003 0.9550 Not Rejected 
Tobacco nonuse 0.808 0.375-1.742 0.297 0.5858 Not Rejected 
BMI (kg/ m2)  
    <25.0 0.122 0.017-0.895 4.065 0.0438 Rejected 
    ≥25.0-29.9  0.885 0.505-1.550 2.766 0.0963 Not Rejected 
Abbreviations: ACS=acute coronary syndromes, BMI=body mass index, CA=coronary 
atherosclerosis, HbA1C=glycated hemoglobin, LDL-C=low density lipoprotein cholesterol 
aReference groups: HbA1C ≥ 7%; female; LDL-C ≥ 100 mg/dL; microalbuminuria (urine 
albumin/creatinine ratio ≥ 30 mg/g); BMI ≥30.0 kg/m2 [Note: SAS used the highest coded number for each 
categorized variable as default reference group] 
b Hypotheses were stated in the null form 




CHAPTER FOUR:    DISCUSSION 
 
 
4.1  CHAPTER OVERVIEW 
The results are discussed in this chapter, along with the strengths and limitations 
of the study, and the study conclusion is presented. 
 
4.2  REVIEW OF STUDY BACKGROUND AND OBJECTIVES 
The leading cause of morbidity and mortality among diabetic patients is 
CVD.[14]  Cardiovascular diseases which consist of CHD, stroke, PVD, hypertension 
and congestive heart failure [3] accounted for approximately 68 percent of deaths in 
diabetic patients in 2004, with CHD as the leading cause.[6]  Coronary heart disease 
consists of acute coronary syndromes (ACS) which include UA, AMI, and small vessel 
coronary artery disease(CAD).[4-5]  After Haffner et al. reported that diabetic patients 
with no prior CAD had the same risk of developing MI as a non-diabetic with established 
CAD, the NCEP revised its lipid guidelines to classify diabetes as a CAD risk equivalent, 
with a 10-year cardiovascular event risk greater than 20 percent.[7, 9]   
To reduce diabetes morbidity and mortality, the ADA recommends targeting 
HbA1C values below seven percent in diabetic patients using a combination of lifestyle 
and pharmacotherapy interventions.[14]  In addition, the ADA recommends aggressive 
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management of other cardiovascular risk factors such as hypertension, high LDL-C, 
microalbuminria and obesity in diabetic patients.   
Although studies have shown a trend of decreasing incidence of cardiovascular 
outcomes with aggressive management of diabetes (i.e., treating to target FBS or 
HbA1C), the reduction in cardiovascular outcomes has not been significant even in well 
designed RCTs that compared intensive blood glucose control to standard control.[47-49, 
53-54].  With the ACCORD study, the rapid decrease in blood glucose over the first year 
in the intensive arm of study was hypothesized to be the cause of increased mortality, 
which eventually led to the premature discontinuation of the study after approximately 
three and one-half years.  With atherosclerosis, studies including diabetic subjects have 
shown a significant association between long-term diabetes and negative changes in the 
vascular wall (IMT and CCA).[37, 46] 
Little is known about the association between mean serial HbA1C values 
preceding an atherosclerotic coronary event and the occurrence of the coronary event.  
The aim of this study was to determine the significance of mean serial HbA1C in 
predicting incident CA or ACS in T2DM patients by comparing a cohort with mean serial 
HbA1C  <7 percent as recommended by the ADA, to a cohort with mean serial HbA1C ≥7 
percent.  The analyses conducted to address the study aim used “real-world” longitudinal 
data of indigent patients receiving routine primary care through the Travis County 




4.3  STUDY FINDINGS 
4.3.1  Objective 1 
This objective described the outcome (CA or ACS), demographic and clinical 
characteristics of T2DM patients included in the analyses.  Although the mean age of 
patients in this study was younger (54 years), there was a higher prevalence of females 
(64%) when compared with other studies.  Recent studies (ACCORD, ADVANCE and 
VADT) which examined the relationship between blood glucose control and 
cardiovascular outcomes had study samples of patients with ages ranging from 60-66 
years and with less than half of the samples comprised of females.[37, 46, 49, 53-54]  
Although race/ethnicity data was not collected, the CommUnityCareTM patient population 
is predominantly Hispanic (74%), with approximately equal proportions of African 
Americans and Caucasians comprising the remaining population.  Because diabetes is 
more prevalent in minority populations and because of the race/ethnicity distribution of 
the clinic population, we are confident that the majority (>50%) of patients in this study 
were minority.  In the ACCORD and VADT studies, Hispanics comprised 16 percent and 
7.2 percent, respectively, while the DCCT had only four percent minority subjects. [47, 
53-54].  In summary, the demographic characteristics of this study sample differ 
compared to other notable studies of diabetes that evaluated cardiovascular event 
outcomes.  Specifically, this study’s patients were younger, and predominantly female 
and minority. 
The mean ± SD HbA1C of patients in this study was 7.8±1.7 percent, which was 
higher than the baseline HbA1C level for the ADVANCE study (7.5 ± 1.6%), but lower 
than baseline HbA1C levels in the ACCORD (8.3±1.1%) and VADT (9.4 ± 2.0%) 
studies.[47, 53-54]  The high HbA1C for the VADT cohort at baseline was because it 
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included subjects who responded poorly to maximal doses of oral antidiabetic agents and 
excluded those with HbA1C <7.5 percent at enrollment.  Among the clinical covariates 
controlled for in this study, only the proportion of subjects with hypertension (defined by 
ICD-9 codes 401.1 or 401.9), differed significantly (p<0.05) between individuals with the 
outcome (100.0%) and individuals without the outcome (80.8%).  The proportion of 
hypertensive patients in the total sample was 81.2 percent which was higher than the 
VADT (72%) study.  The proportion of hypertensive patients was not provided by the 
ACCORD, ADVANCE, DCCT and UKPDS studies; instead, those studies presented 
averages of systolic and diastolic pressures.[47-48, 53-54]. 
Regarding the other clinical covariates, two-thirds of the sample used statin 
medications (66.6%) and 64 percent of subjects were obese with a mean BMI±SD of 
33.8±8.3 kg/m2. The proportion of the sample that used a statin was similar to the 
ACCORD study (62%), but higher than the ADVANCE study (47% at the end of follow-
up).[[49, 54]  Mean BMI values in this study were similar to the VADT and ACCORD 
studies (31.3 kg/m2 and 32.5 kg/m2, respectively), but higher than the ADVANCE (28.5 
kg/m2) study, which included subjects from Europe, Australia and Asia, in addition to 
North America.[49, 53-54]   
The following covariates were observed in less than 50 percent of this study’s 
sample: LDL-C ≥100 mg/dL, microalbuminuria, aspirin use, insulin use and current 
tobacco use.   This study had 35 percent of the total sample and 27.4 percent of those 
with the outcome (CA or ACS) with LDL-C ≥100 mg/dL closest to their respective end 
dates.  The high percentage of statin use (67%) could explain why 65 percent of the 
sample had LDL-C <100 mg/dL, which is the goal set by the ADA and the National 
Cholesterol Education Program (NCEP) to improve cardiovascular outcomes.[9, 14]  
Other studies reported mean LDL-C values that were at or close to the goal set by the 
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ADA.[49, 53-54]  In the VADT, the mean LDL-C at the end of follow-up was 80 mg/dL, 
lower than what was reported for the ADVANCE (102 mg/dL) and ACCORD (105 
mg/dL) studies.  The proportion of subjects who used a statin in this study (67%) is 
similar to the ACCORD (62%) study, but higher than the multi-continental ADVANCE 
study which had 47 percent of its subjects using a statin at the end of follow-up period.   
Microalbuminuria was present in 29 percent of subjects in this sample, which is 
slightly higher than the microalbuminuira history recorded in the ADVANCE study 
(27%).  After a maximum follow-up of seven years in the VADT study, 11.5 percent of 
subjects progressed from normoalbuminuria to microalbuminuria, but standard therapy 
and intensive therapy did not differ significantly in the rate of progression.[53]   
The rate of aspirin use (44.6%) in this study was lower than what was reported in 
the ACCORD study (54.5%), which was an epidemiologic study conducted in 10,251 
patients in the US and Canada.[54]  However, aspirin use was similar to the ADVANCE 
study at baseline (43.8%), but not the end of follow-up where the reported use of aspirin 
rose to 56 percent.[49]  VADT used a more aggressive approach for aspirin use and 
prescribed aspirin for all enrolled subjects unless contraindicated.[53]  The reason why 
less than half of this study sample was not on aspirin could be explained by under-
reporting of aspirin use by subjects who are required to purchase aspirin over-the-counter 
(versus receiving aspirin through the clinic) for cardiovascular prophylaxis.  Since the 
study follow-up period ended in September 2009, the low rate of aspirin use was not a 
result of the recommendations by the ADA guideline taskforce in November 2009 to 
curtail aspirin use to only high-risk diabetic patients.[14]    
Approximately one-third of the CommUnityCareTM study sample (33.5%) used 
insulin as part of their diabetes regimen, which was similar to the ACCORD cohort at 
baseline (34.9%).[54]  Since ACCORD recruited patients throughout the US, the 
56 
 
proportion of patients on insulin in its large sample (10,251 patients) provided a broad 
“snapshot” of insulin use across various medical practices nationwide.  Hence 
CommUnityCareTM health professionals’ insulin prescribing patterns are similar to other 
providers across the country.  Similarly, the VADT sample, with a higher mean HbA1C at 
enrollment (9.4%) had a baseline insulin use of 35 percent. On the contrary, the 
ADVANCE sample had baseline insulin use of 1.5 percent which increased to 40 percent 
in the intensive arm at the end of follow-up.[49, 53]  This number may have been low at 
baseline due to an exclusion criterion of having a definite indication for insulin for long-
term treatment at the time of enrollment.   
The smoking rate in this study sample was 12.5 percent which was lower than in 
the following studies: ACCORD (14%), ADVANCE (14%), VADT (17%), UKPDS 
(31% ), and DCCT (18%).[47-49, 53-54]  Perhaps the UKPDS study had current tobacco 
use approximately twice that of ACCORD and ADVANCE because at the time that the 
UKPDS study was started (1977), smoking cessation was not a focus in the prevention of 
cardiovascular events.[48-49, 54]   
In summary, for each covariate (demographic or clinical characteristic) in this 
study, there were one or more prospective studies with similar characteristics, with the 
exception of race and gender.  Education, mean duration of diabetes, previous 
cardiovascular event, other antiplatelet agents, oral hypoglycemic agents and waist 
circumference were matching variables in some of the prospective studies.  However, 
these were not included in the present study.   
 The rate of the outcome (CA or ACS) in this study was two percent over a mean 
follow-up of approximately 2 years (1.8 years), which is lower than reported by 
Avogadro et al. (1.9% per year) and the Atherosclerosis Risk in Communities Study 
(ARIC) (1.4% per year).[61-62]  Both Avogadro et al. and ARIC were prospective cohort 
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studies to determine incidence of CHD in diabetic patients and they followed diabetic 
patients for longer periods of time (minimum of 4 and 8 years respectively) compared to 
this study.  Also, Fox et al. calculated from the original cohort of the Framingham risk 
study (which the NCEP ATP III guidelines for prevention of cardiovascular disease were 
based), a ten-year risk odds ratio of CVD of 21.6 percent (95% CI=9.5-33.6) for females 
and 28.2 percent (95% CI=15.4-41.1) for males with diabetes respectively.[63]  Another 
reason for the lower event rates in this study could be explained by the narrow definition 
of the outcome using ICD-9 codes for CA or ACS.  Avogadro et al. included patients 
with coronary vessel occlusion who had undergone coronary artery bypass graft or 
percutaneous transluminary coronary angioplasty.[61]  Furthermore, ACCORD, 
ADVANCE and VADT had 32-40 percent of the study population with prior history of 
CVD, which put them at a higher risk for a subsequent cardiovascular event.[49, 53-54]  
Finally, the lower incidence rate of the outcome in this study could be explained by 
aggressive management of cardiovascular risk factors (lower rates of smoking, statin use 
and LDL-C management).  Having data on diabetic retinopathy (an independent risk 
factor for cardiovascular complications in diabetic patients) could have provided a better 
perspective of the risk of macrovascular complications of this study sample since 
retinoapathy can be present in diabetic patients at the time of diabetes diagnosis.[23]  The 
higher proportion of females (64.2%) compared to males in this study (35.8%) may also 
account for the low incidence rate of the outcome since females have a higher risk of CA 





4.3.2  Objective 2 
This objective examined the bivariate unadjusted relationship between the 
outcome (CA or ACS) and HbA1C.  Although a chi-square test did not show a significant 
relationship (p=0.5834) between CA or ACS and dichotomized mean serial HbA1C, 
subjects with mean HbA1C ≥7 percent had a higher percentage of subjects with incident 
CA or ACS compared to those with HbA1C <7 percent (58.1 vs. 41.9).  Insufficient 
power may explain why the results were not significant in the present study.  However, 
other large prospective randomized studies (N=1441-11140) did not find a significant 
difference in the incidence of CVD and tight glycemic control.[47-49, 53-54] 
Contrary to the nonsignificant chi-square analysis in this study, unadjusted 
analyses from two prospective studies (ACCORD and UKPDS) showed significant 
associations between cardiovascular event outcomes and HbA1C.  The ACCORD 
researchers conducted a subgroup analysis in which they evaluated the unadjusted 
relationship between the primary outcome (a composite of MI, stroke, and death from 
cardiovascular causes) and baseline HbA1C and found a significant relationship 
(increased risk) between the primary outcome and baseline HbA1C (i.e., ≤8% compared 
to >8%).  Similarly, Stratton et al reported an increasing ten-year risk for cardiovascular 
events with increasing mean updated HbA1C categories (i.e., <6%, 6-<7%, 7-<8%, 8-
<9%, 9-<10% and ≥10%) in an unadjusted regression model using the UKPDS data.[63]  
Using the lowest HbA1C category as a reference, the risk of each of the clinical outcomes 
(any complications or death related to diabetes and all cause mortality, myocardial 
infarction, stroke, lower extremity amputation and microvascular disease) rose with mean 
updated HbA1C before and after adjustment for age, sex, ethnic group, lipid 
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concentration, smoking, blood pressure and albuminuria.  Thus, this study’s results are 
congruent with the majority of studies conducted that examined the relationship between 
HbA1C and CA or ACS. 
 
 
4.3.3  Objective 3 
Objective 3 assessed the association between the outcome (incident CA or ACS) 
and mean serial HbA1C (i.e., <7% compared to ≥7%) in the study sample after 
controlling for age, gender, hypertension, LDL-C, microalbuminuria, aspirin use, statin 
use, insulin use, tobacco use and BMI.  The results showed no significant association 
between the incidence of CA or ACS in T2DM patients and mean serial HbA1C. The 
results of the logistic regression supports the lack of significant association between 
HbA1C and cardiovascular outcomes found in several larger prospective studies that 
controlled for multiple risk factors. [17, 47-49, 53-54, 64]    
Regarding the covariates, only three were significantly related to the outcome.  
Increasing age, male gender and BMI ≥ 30 kg/m2 (compared with BMI <25 kg/m2) were 
significantly associated with incident CA or ACS.  Age, gender, LDL-C and hypertension 
diagnosis were cardiovascular risk factors that differed significantly at baseline between 
diabetic patients who developed incident CHD and those who did not in the ARIC 
epidemiological study, which followed 1,626 diabetic patients for eight years.[62].  
Among the 186 incident CHD events reported (incidence rate = 11.4%) in the ARIC 
study, participants with incident CHD were older at baseline (mean age at baseline of 57 
years), and more likely to be male (57%) when compared with diabetic cohort with no 
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events (p<0.001 for both comparisons).  However, in the ARIC study, BMI (31 kg/m2) at 
baseline was similar between the diabetic subjects who developed incident CHD and the 
diabetic subjects who did not over the study period.[62]  Nevertheless, the impact of 
obesity (BMI ≥ 30 kg/m2) on CVD risk should not be ignored based on the findings of 
Fox et al. who evaluated data from the Framingham heart study.  The Framingham heart 
study was an epidemiological risk study conducted in predominantly white middle class 
subjects in Framingham, MA.  The study examined the ten-year risk of developing CVD 
and found that among diabetic patients, CVD was higher in obese subjects compared to 
normal weight individuals.  In normal weight diabetic men and women, the ten-year risks 
(HR, 95% CI) of developing CVD were 33.2 (6.3-60.0) and 9.4 (0.0-22.1) respectively; 
while in obese subjects, the risks increased to 47.6 (12.1-83.2) and 41.9 (14.2-69.6), 
respectively.[63] 
The lack of significant risk reduction in outcome (per logistic regression) by the 
interventions targeted at cardiovascular risk reduction (aspirin use, statin use, 
nonsmoking, LDL-C < 100 mg/dL, and normoalbuminuria) may be due to lack of power 
in this study.  These factors are among the primary preventive interventions to reduce 
cardiovascular complications in T2DM patients.[14].  The landmark Steno-2 study, 
which was conducted in T2DM patients with microalbuminuria in Denmark, reported that 
comprehensive multifactorial interventions (blood pressure, blood glucose, lipid control, 
ACE inhibitor use, aspirin use, smoking cessation, healthcare provider education and 
motivation, and lifestyle changes) reduced the risk of cardiovascular and microvascular 
complications by 50 percent, with the benefits persisting five years after the study follow-
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up.[17, 65]  Also, the Copenhagan male study showed that high TG and low HDL-C 
commonly seen in T2DM patients was as powerful predictor of CHD as LDL-C 
alone.[33]  It is therefore important for clinicians to follow a multifactorial interventional 
approach as was employed in the Steno-2 study, in addition to glycemic control in T2DM 
to comprehensively reduce incidence of CVD.   
Since this study used data from “real-life” patient follow-up, it is possible that 
patients who were treated aggressively for their diabetes to lower HbA1C levels were also 
the patients who were already at the highest risk for CVD at the time of diabetes 
diagnosis.  If that was the case, then aggressively treating their diabetes to a lower HbA1C 
target, while concurrently targeting cardiovascular risk factors were not enough to avert 
the incidence of the outcome as was observed in the ACCORD subgroup analysis, which 
showed that increased mortality in the intensive group with target HbA1C <6.5 percent 
was higher among patients at high risk (prior history of CVD) at baseline.[54]   
In the era of rising healthcare costs, it is important to consider the benefit or risk 
reduction attained from lowering HbA1C to currently recommended targets.  Such 
information will be beneficial in budgeting the use of healthcare dollars especially for the 
minority population, who have a higher incidence of CVDs.  It is also important to 
consider when serving patients who are indigent and/or who depend on public funding 
for their health needs, such as the CommUnityCareTM patients.  From the author’s 
experience in clinical practice, treating diabetic patients and helping them maintain ADA 
target HbA1C levels require significant healthcare resources (e.g., medications, insulin, 
glucometer, lancets, test strips, laboratory tests and medical interventions for 
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hypoglycemia).  Patients must also contribute significant effort and commitment to 
lifestyle changes and medication adherence.  Therefore, if the benefit of HbA1C reduction 
in decreasing CVD risk in certain categories of patients (e.g., shorter life expectancy, 
history of hypoglycemia requiring medical care, established microvascular and 
macrovascular complications), is not comparable to the cost involved, then resources may 
need to be channeled to treat other nonglycemic cardiovascular risk factors.   
Finally, this study included atherosclerosis (a precursor to CVD) as an endpoint 
and did not find an association between mean serial HbA1C over two years and incidence 
of CA or ACS.  This is contrary to the prospective studies which use hard endpoints of 
clinical events such as MI, CHD (ACS), stroke and even death.  It may be beneficial 
(medically and economically) to identify the existence of subclinical asymptomatic 
disease (e.g., atherosclerosis) in order to start early management and avert additional 
morbidity (from CVD event which have irreversible damage) or mortality.  One such 
study, MESA (Multi-Ethnic Study of Atherosclerosis), is examining these issues.  The 
ongoing epidemiologic study includes a more diverse population (38% white, 28% 
African American, 23% Hispanic and 11% Asians) and it aims to provide insight 
regarding which risk factors of atherosclerosis are more important to target, and what 
interventions (pharmacologic and lifestyle) in “real-world” longitudinal primary care will 
slow or totally prevent the progression from subclinical atherosclerosis to overt CHD 
events.[66]  The NCEP ATP III guidelines for predicting the ten-year risk for 
atherosclerosis and CVD from cardiovascular risk factors for appropriate prophylactic 
interventions was based on the data from the Framingham study with predominantly 
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white subjects. Similarly, the ten-year prospective cohort-diverse MESA study might 
provide information about whether HbA1C should be added to the cardiovascular risk 
prediction charts.  
 
4.4  STUDY LIMITATIONS 
In spite of having several strengths such as a predominant Hispanic population 
and a fairly comprehensive database for clinical and demographic factors, this study has 
several limitations.  First, race was not adjusted for in this study as was done with most of 
the prospective diabetes studies evaluating cardiovascular outcomes.  However, since 
approximately three-quarters of the population served by CommUnityCareTM are 
Hispanic, these results are generalizeable to the low-income Hispanic population who 
were seen for approximately two years by a CommUnityCareTM network provider.  A 
second limitation is the accuracy and completeness of ICD-9 diagnoses for CVD in a 
primary care setting.  When patients have CVD complications, they are often hospitalized 
and/or referred to cardiologists, who make the diagnosis.  It is possible that notes from 
other providers are not recorded in the primary care providers’ medical record, which 
could lead to under-diagnosis.  Similarly, atherosclerosis is a ‘silent’ disease state, which 
typically goes undiagnosed until a symptomatic event has occurred.  Another limitation 
was variation in the number of HbA1C values available for each patient with some 
patients having only two (one in each calendar year) and others having up to four or more 
values in a calendar year.  The mean follow-up period was 1.8 years, which probably did 
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not allow time for long-term accumulation of vascular damage.  This, in addition to lack 
of documentation and under-diagnosis, could have led to low incidence rates in this 
study.  With any EMR study, the data are only as accurate as the coding.  Specific 
medications and medication taking behaviors (e.g., prescription claims) were not 
included.  This information may have helped understand patient disease severity as well 
as medication adherence.  Finally, there were other risk factors that were not accounted 
for because of the subjective nature or lack of reliability in reporting and documentation.  
These include duration of diabetes, alcohol intake, diet and physical activity.   
 
 
4.5  CONCLUSIONS AND FUTURE RESEARCH 
This study of T2DM patients which adjusted for multiple cardiovascular risk 
factors did not find a significant association between incident CA or ACS and mean serial 
HbA1C (HbA1C ≥7% compared to <7%) over a mean follow-up of approximately two 
years.  This observed lack of benefit may be due to other interventions leading to 
decreased cardiovascular risk that was not adjusted for in this study including HDL-C, 
blood pressure changes, weight changes and the use of ACE inhibitors.  Future studies 
should consider using larger sample size and longer treatment duration to identify the 
specific modifiable cardiovascular risk factors including those not adjusted for in this 
study that could be targeted in the same population cohort used in the study.  Also, more 
detailed information on adherence and persistence to relevant pharmacotherapy (diabetes, 
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